Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06024499
PHASE2

Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

Sponsor: Shaperon

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.

Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of HY209 Gel in Patients With Mild to Moderate Atopic Dermatitis(AD)

Key Details

Gender

All

Age Range

18 Years - 100 Years

Study Type

INTERVENTIONAL

Enrollment

210

Start Date

2024-03-01

Completion Date

2026-08-31

Last Updated

2026-02-23

Healthy Volunteers

No

Interventions

DRUG

HY209GEL Active

Selected two among four doses (HY209GEL 0.5% or 1% or 2% or 4%) in PART1

OTHER

Placebo

Placebo

Locations (12)

Cahaba Dermatology Skin Health Center

Birmingham, Alabama, United States

RAOOF MD Dermatology

Encino, California, United States

L.A. Universal Research Center, Inc.

Los Angeles, California, United States

Zenith Research Inc.

Los Angeles, California, United States

Continental Clinical Solutions, LLC

Towson, Maryland, United States

Revival Research Institute, LLC

Southfield, Michigan, United States

Sadick Dermatology

New York, New York, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Gachon University Gil Medical Center

Seoul, South Korea

Seoul National University Bundang Hospital

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Severance Hospital, Yonsei University Health System

Seoul, South Korea